Pharmaceutical Product Development Inc
Pharmaceutical Product Development — Earnings Presentation (October 2010)
16 slides from Pharmaceutical Product Development's earnings presentation, Oct 26, 2010
Slide 1: GAAP / Non-GAAP Reconciliation
Exhibit 99.3 GAAP / Non-GAAP Reconciliation A leading global CRO
Slide 2: Regulation G
Regulation G From time to time, PPD discloses selected non-GAAP financial measures. For example, we disclose net revenue excluding reimbursed out-of-pockets because these third party expenses are reimbursed to us by our clients, are not directly related to the services we provide and do not have any
Slide 3: GAAP/Non-GAAP Reconciliation: Net Revenue, Net Income and EPS (2005-2009)
GAAP/Non-GAAP Reconciliation Net Revenue, Net Income and EPS (2005-2009) (in thousands, except per share data) 2005 2006 2007 2008 2009 Net Revenue: Net Revenue, per GAAP $ 1,037,090 $ 1,247,682 $ 1,414,465 $ 1,551,384 $ 1,416,770 Less: Reimbursed out-of-pockets 75,074 101,383 119,087 117,132 101,00
Slide 4: GAAP/Non-GAAP Reconciliation: Net Revenue, Net Income and EPS (2000-2004)
GAAP/Non-GAAP Reconciliation Net Revenue, Net Income and EPS (2000-2004) (in thousands, except per share data) 2000 2001 2002 2003 2004 Net Revenue: Net Revenue, per GAAP $ 372,650 $ 460,633 $ 608,657 $ 726,983 $ 841,256 Less: Reimbursed out-of-pockets 27,332 29,092 46,008 57,485 67,316 Net Revenue
Slide 5: GAAP/Non-GAAP Reconciliation (FY'08 & FY'09)
GAAP/Non-GAAP Reconciliation Gross Margin and Operating Margin (FY’08 & FY’09) Twelve Months Ended December 31, (in thousands) Item 2008 2009 Net Revenue: Net Revenue, per GAAP 1 $ 1,551,384 $ 1,416,770 Less: Reimbursed out-of-pockets 2 117,132 101,003 Net Revenue less reimbursed out-of-pockets 3 $
Slide 6: Development Segment (FY'08 & FY'09)
GAAP/Non-GAAP Reconciliation Development Segment Gross Margin and Operating Margin (FY’08 & FY’09) Twelve Months Ended December 31, (in thousands) Item 2008 2009 Net Revenue: Net Revenue, per GAAP 1 $ 1,532,679 $ 1,410,294 Less: Reimbursed out-of-pockets 2 116,850 100,840 Net Revenue less reimbursed
Slide 7: GAAP/Non-GAAP Reconciliation (Q1'09 & Q1'10)
GAAP/Non-GAAP Reconciliation Gross Margin and Operating Margin (Q1’09 & Q1’10) Three Months Ended March 31, (in thousands) Item 2009 2010 Net Revenue: Net Revenue, per GAAP 1 $ 364,370 $ 346,769 Less: Reimbursed out-of-pockets 2 23,854 22,649 Net Revenue less reimbursed out-of-pockets 3 $ 340,516 $
Slide 8: Development Segment (Q1'09 & Q1'10)
GAAP/Non-GAAP Reconciliation Development Segment Gross Margin and Operating Margin (Q1’09 & Q1’10) Three Months Ended March 31, (in thousands) Item 2009 2010 Net Revenue: Net Revenue, per GAAP 1 $ 359,208 $ 346,476 Less: Reimbursed out-of-pockets 2 23,854 22,649 Net Revenue less reimbursed out-of-po
Slide 9: GAAP/Non-GAAP Reconciliation (Q2'09 & Q2'10)
GAAP/Non-GAAP Reconciliation Gross Margin and Operating Margin (Q2’09 & Q2’10) Three Months Ended June 30, (in thousands) Item 2009 2010 Net Revenue: Net Revenue, per GAAP 1 $ 354,598 $ 369,919 Less: Reimbursed out-of-pockets 2 24,257 28,423 Net Revenue less reimbursed out-of-pockets 3 $ 330,341 $ 3
Slide 10: Development Segment (Q2'09 & Q2'10)
GAAP/Non-GAAP Reconciliation Development Segment Gross Margin and Operating Margin (Q2’09 & Q2’10) Three Months Ended June 30, (in thousands) Item 2009 2010 Net Revenue: Net Revenue, per GAAP 1 $ 354,436 $ 362,202 Less: Reimbursed out-of-pockets 2 24,257 28,423 Net Revenue less reimbursed out-of-poc
Slide 11: Operating Margin (Q3'09 & Q3'10)
GAAP/Non-GAAP Reconciliation Operating Margin (Q3’09 & Q3’10) Three Months Ended September 30, (in thousands) Item 2009 2010 Net Revenue: Net Revenue, per GAAP 1 $ 340,400 $ 365,375 Less: Reimbursed out-of-pockets 2 24,117 25,985 Net Revenue less reimbursed out-of-pockets 3 $ 316,283 $ 339,390 Opera
Slide 12: Net Revenue, Operating Income and Operating Margin (Q1'09 - Q4'09)
GAAP/Non-GAAP Reconciliation Net Revenue, Operating Income and Operating Margin (Q1'09 - Q4'09) (in thousands) Item Q1'09 Q2'09 Q3'09 Q4'09 Net Revenue: Net Revenue, per GAAP 1 $ 364,370 $ 354,598 $ 340,400 $ 357,239 Less: Reimbursed out-of-pockets 23,854 24,257 24,117 28,612 Less: Discovery Science
Slide 13: Net Revenue, Operating Income and Operating Margin (Q1'10 - Q3'10)
GAAP/Non-GAAP Reconciliation Net Revenue, Operating Income and Operating Margin (Q1'10 - Q3'10) (in thousands) Item Q1'10 Q2'10 Q3'10 Net Revenue: Net Revenue, per GAAP 1 $ 346,769 $ 369,919 $ 365,375 Less: Reimbursed out-of-pockets 22,649 28,423 25,985 Less: Discovery Sciences revenue 293 7,717 - N
Slide 14: GAAP/Non-GAAP Reconciliation (Q4'08 & Q4'09)
GAAP/Non-GAAP Reconciliation Gross Margin and Operating Margin (Q4’08 & Q4’09) Three Months Ended December 31, (in thousands) Item 2008 2009 Net Revenue: Net Revenue, per GAAP 1 $ 363,139 $ 357,402 Less: Reimbursed out-of-pockets 2 24,321 28,775 Net Revenue less reimbursed out-of-pockets 3 $ 338,818
Slide 15: Development Segment (Q4'08 & Q4'09)
GAAP/Non-GAAP Reconciliation Development Segment Gross Margin and Operating Margin (Q4’08 & Q4’09) Three Months Ended December 31, (in thousands) Item 2008 2009 Net Revenue: Net Revenue, per GAAP 1 $ 362,814 $ 356,692 Less: Reimbursed out-of-pockets 2 24,105 28,612 Net Revenue less reimbursed out-of
Slide 16: Net Income and EPS (Q4'08 & Q4'09)
GAAP/Non-GAAP Reconciliation Net Income and EPS (Q4’08 & Q4’09) Three Months Ended December 31, (in thousands, except per share data) 2008 2009 Net Income, per GAAP $ 47,198 $ 18,991 Plus: Impairment of investments 2,306 2,076 Plus: Impairment of intangibles - 10,361 Plus: Bad debt expense associate
Pharmaceutical Product Development — Earnings Presentation (October 2010) on 6ix